Most people with capital can find public stocks. Finding early longevity biotechnology companies, understanding what they are building and deciding which deserve more attention is much harder. This page records EverLife’s decisions so you can see each company’s entry date, valuation, score and what happened next.
How to read this page
Tracker: companies with an active research thesis and enough evidence, valuation information and access for ongoing monitoring. The Tracker is a dated research record, not a buy list.
Scout: companies that are close, but still need one or more important pieces, such as stronger human evidence, a supportable valuation or usable investment terms.
Watchlist: earlier companies or mechanisms worth following. Each has a specific result that could justify a new Scout review.
When a company moves, EverLife records the date, score and publicly supportable valuation at that point. Historical entries remain visible so readers can judge the process over time.
Latest classification update, August 2, 2026: BioAge Labs moved from Scout to Tracker. Cambrian Bio and Immunis Biomedical moved from Watchlist to Scout. Maxwell Biosciences moved to Watchlist because it did not clear the current Scout requirements.
Important disclosure: EverLife publishes independent, impersonal educational research. Nothing on this page is investment, legal, tax or medical advice, an offer, solicitation or recommendation. Early-stage biotechnology is speculative and can result in total loss. Private securities may be inaccessible or illiquid. Valuation estimates use public information and may differ materially from actual transaction prices. Eric Pemper holds personal equity in Repair Biotechnologies and Yuva Biosciences.
The Tracker is public so readers can judge the historical record. Premium members receive Scout and Watchlist names, scores, valuations and the milestones that could change each classification. Public-company values use market value near the entry date. Private-company figures are labeled estimates; when no newer public mark exists, the page says so.
Research Tracker
Company | Entry date and valuation | 25-gate score | What changed since entry |
|---|---|---|---|
Pre-Beehiiv record, May 8, 2026. Entry value: roughly $45M-$65M public-data estimate; cash not publicly disclosed. | 3.19 (added under older framework) | May 12, 2026: FDA granted REP-0003 RDEP eligibility for HoFH. Regulatory-path progress, not approval or human-efficacy evidence. | |
July 31, 2026. Entry value: $160M-$240M Dealroom estimate; cash not publicly disclosed. | 3.68 (added under older framework) | No verified post-entry change recorded. | |
Pre-Beehiiv record, May 8, 2026. Entry value: about $30.4M third-party estimate; cash not publicly disclosed. | 3.48 (added under older framework) | May 14, 2026: company reported Phase 1 human mobilization and excretion of 7-ketocholesterol with UDP-003. Target engagement, not plaque regression or clinical benefit. | |
July 31, 2026. Entry value: $424M-$636M Dealroom estimate; $105M Series B announced, but cash not separately disclosed. | 3.70 (added under older framework) | No verified post-entry change recorded. | |
Pre-Beehiiv record, May 8, 2026. Entry value: about $45M third-party estimate; cash not publicly disclosed. | 2.94 (added under older framework) | No verified post-entry change recorded. | |
July 31, 2026. Entry value: $366M-$900M range across public third-party estimates; $181.4M Series D announced, but cash not separately disclosed. | 3.55 (added under older framework) | No verified post-entry change recorded. | |
July 19, 2026. Entry market value: about HK$28.8B, approximately US$3.7B; US$393.3M cash at December 31, 2025. | 4.18 | Since the July 19 entry: on July 22, Insilico nominated ISM9528, its 31st reported preclinical candidate, for a brain-penetrant non-opioid pain program. On July 27, it announced that first-human ISM6331 data were accepted for an ESMO rapid oral presentation. These are pipeline-execution milestones, not proof of approval, patient benefit or platform-wide repeatability. | |
July 31, 2026. Entry value: about $36.4M third-party estimate; $7.6M June financing first close, but cash not separately disclosed. | 3.73 (added under older framework) | No verified post-entry change recorded. | |
July 31, 2026. Entry market value: about $450M; $224.9M cash and marketable securities at March 31, 2026. | 3.92 (v4.1 rescore, Aug. 2, 2026) | No verified post-entry change recorded. | |
June 3, 2026. Entry value: $160M-$240M Dealroom estimate; cash not publicly disclosed. | 3.32 (added under older framework) | June 15, 2026: company reported preliminary Phase 1b/2a RLS-1496 results, including 46% fewer actinic-keratosis lesions at four weeks with minimal irritation. Preliminary local skin evidence, not systemic rejuvenation. | |
BioAge Labs | Scout July 31; Tracker August 2, 2026. Entry market value: about $970M; $384.9M cash and marketable securities at March 31, 2026. | 3.91 (Aug. 2 audit) | Moved from Scout to Tracker on August 2 after the full-framework rescore. Public valuation and access are usable; the active mid-stage obesity study and disclosed financial position support security-level monitoring. |
The deeper research section is for Premium members.
Free readers get the big idea: the mechanism, disease area, industry pattern, and why it may matter. Premium members get the company comparison, 25-Gate Framework reasoning, tracker or watchlist decision, functional-overlap analysis, and the caveats behind the conclusion.
Start Free 7-Day TrialPremium members get::
- Company names and side-by-side comparisons
- 25-Gate Framework reasoning
- Tracker and watchlist decision logic
- Smart money and pharma move notes when relevant
- Honest caveats around risk and uncertainty
- Access to the premium research archive